KR20180127407A - 암 요법용 조작된 trail - Google Patents

암 요법용 조작된 trail Download PDF

Info

Publication number
KR20180127407A
KR20180127407A KR1020187029745A KR20187029745A KR20180127407A KR 20180127407 A KR20180127407 A KR 20180127407A KR 1020187029745 A KR1020187029745 A KR 1020187029745A KR 20187029745 A KR20187029745 A KR 20187029745A KR 20180127407 A KR20180127407 A KR 20180127407A
Authority
KR
South Korea
Prior art keywords
ser
gly
leu
lys
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187029745A
Other languages
English (en)
Korean (ko)
Inventor
다이아나 훙-이 카이 마르칸토니오
스티븐 엘 사진스키
비르기트 엠 쇼에베를
에릭 엠 탐
Original Assignee
메리맥 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메리맥 파마슈티컬즈, 인크. filed Critical 메리맥 파마슈티컬즈, 인크.
Publication of KR20180127407A publication Critical patent/KR20180127407A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187029745A 2016-03-16 2017-03-16 암 요법용 조작된 trail Withdrawn KR20180127407A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US62/309,352 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US62/323,501 2016-04-15
US201762445556P 2017-01-12 2017-01-12
US62/445,556 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (1)

Publication Number Publication Date
KR20180127407A true KR20180127407A (ko) 2018-11-28

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029745A Withdrawn KR20180127407A (ko) 2016-03-16 2017-03-16 암 요법용 조작된 trail

Country Status (10)

Country Link
US (1) US20190077870A1 (enExample)
EP (1) EP3430034A1 (enExample)
JP (1) JP2019518713A (enExample)
KR (1) KR20180127407A (enExample)
CN (1) CN108884142A (enExample)
AU (1) AU2017234679A1 (enExample)
CA (1) CA3017622A1 (enExample)
IL (1) IL261267A (enExample)
MX (1) MX2018011219A (enExample)
WO (1) WO2017161173A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080865A3 (ko) * 2020-10-13 2022-08-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
KR20190017804A (ko) * 2016-06-13 2019-02-20 메리맥 파마슈티컬즈, 인크. 환자를 선별하고 trail-기반 치료제 또는 사멸 수용체 효능제로 치료하는 방법
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
JP5118796B2 (ja) * 1999-06-28 2013-01-16 ジェネンテック, インコーポレイテッド 二価の金属イオンを利用したApo−2リガンドの製造方法
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス,インコーポレーテッド FcγRIIB特異的抗体とその利用法
CA2499816C (en) 2002-09-27 2013-07-30 Xencor, Inc. Optimized fc variants and methods for their generation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
PL2310509T3 (pl) * 2008-07-21 2015-08-31 Apogenix Ag Jednołańcuchowe cząsteczki TNFSF
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
US20120134984A1 (en) * 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
WO2011139681A1 (en) 2010-04-26 2011-11-10 Merrimack Pharmaceuticals Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
CN111592601A (zh) * 2011-07-06 2020-08-28 江苏靶标生物医药研究所有限公司 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用
NO2776305T3 (enExample) * 2014-04-23 2018-01-27
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022080865A3 (ko) * 2020-10-13 2022-08-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Also Published As

Publication number Publication date
IL261267A (en) 2018-10-31
US20190077870A1 (en) 2019-03-14
WO2017161173A1 (en) 2017-09-21
CA3017622A1 (en) 2017-09-21
EP3430034A1 (en) 2019-01-23
MX2018011219A (es) 2019-01-10
AU2017234679A1 (en) 2018-08-30
JP2019518713A (ja) 2019-07-04
CN108884142A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
JP7587656B2 (ja) Pd-l1及びcd137に結合する抗体分子
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
US11377477B2 (en) PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
TWI853809B (zh) 包含4-1bbl之靶向her2的抗原結合分子
TW202227494A (zh) 多特異性免疫靶向分子及其用途
KR20220016945A (ko) 다중특이적 단백질
KR20180031728A (ko) 다가 및 다중특이적 gitr 결합 융합 단백질
JP2020512814A (ja) 免疫抱合体
CA2956126A1 (en) Sirp-alpha immunoglobulin fusion proteins
KR20140054268A (ko) 탠덤 fc 이중특이적 항체
JP2022531306A (ja) CLEC12a結合性ポリペプチド及びその使用
JP2022531765A (ja) Cd33結合性ポリペプチド及びその使用
KR20180127407A (ko) 암 요법용 조작된 trail
CN111465618A (zh) 双特异性cd16-结合分子及其在疾病治疗中的用途
JP2023524995A (ja) イヌpd-1結合性ポリペプチド及びその使用
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
KR20230024408A (ko) 항-cldn-18.2 항체 및 그 용도
RU2826084C2 (ru) МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137
RU2777573C2 (ru) Антитела против 4-1bb человека и их применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200313

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210305